Enzymatic Release of N-Glycan
Studying the structural and biological function of glycans is essential to understand the mechanism of various biological activities. CD BioGlyco has developed a series of outstanding Enzymatic Cleavage methods by integrating various advanced technologies to provide Glycan Release services.
Overview of N-Glycan
N-Glycosylation is a common post-translational modification that affects glycoprotein structure and function. N-Glycans are attached to the nitrogen (N) atom in the asparagine (Asn) side chain of the sequon. Glycomic analysis of these intact N-glycans has the potential to lead to therapeutic targets and potentially to treat many genetic defects and their diseases. For example, comparing the glycan profiles of patients and healthy individuals to indicate disease and possible treatment pathways. Studying N-glycans relies on their intact release from glycoproteins, followed by mass spectrometry (MS) techniques analysis.
Fig.1 Workflow for the analysis of N-glycans in glycoproteins. (Regan, et al., 2019)
There are 2 common methods to release N-glycans: chemical release and enzymatic release. Peptide: N-glycosidase F (PNGase F) is the most widely used method for N-glycan release, which releases intact N-glycans to keep the peptide backbone intact. Endoglycosidase H (Endo H) only releases high-mannose N-glycans or hybrid N-glycans. Glycopeptidase A (PNGase A) cleaves all high-mannose, hybrid, and short-complex N-glycans, but fails to release glycans containing sialic acid residues. Hydrazinolysis and β-elimination are the two main chemical release techniques. Both methods are used to release intact glycans from the peptide backbone, but they result in the degradation of the peptide backbone. Therefore, enzymatic methods have become the method of choice for N-glycan release.
The potential applications of N-linked glycosylation in the pharmaceutical field are becoming increasingly apparent. Many therapeutic antibodies on the market are N-linked glycoproteins. In addition, researchers have genetically engineered therapeutic glycoproteins with human-like N-linked glycans. Therefore, the development of efficient glycan release services is necessary.
Key Technologies
CD BioGlyco employs a suite of highly specific glycosidases as core technologies for the enzymatic release of N-glycans. The choice of enzyme is critical and depends on the type of N-glycan, the source material, and the specific analytical goals. Our primary enzymes include:
- PNGase F: Cleave all types of Asp-linked glycans (high-mannose, hybrid, and complex) from glycoproteins
- Endo H: Cleave the chitobiose core of the glycan, leaving one GlcNAc residue still attached to the Asp on the protein.
- Endoglycosidases F1, F2, F3 (Endo F1, Endo F2, and Endo F3): A family of enzymes with distinct specificities.
Enzymatic Release N-Glycan at CD BioGlyco
N-Glycans are essential for physiological and pathological processes. A reliable method must be identified to better separate N-glycans from proteins before analysis. Conventional methods include enzymatic release methods and Chemical Release methods. At CD BioGlyco, we have developed an advanced glycan release platform to provide clients with efficient and accurate N-glycan release services on antibodies, fusion proteins, and other N-glycosylated proteins via PNGase F. We successfully hydrolyze the amide bond between the Asn and N-glycans (including high-mannose, complex, and hybrid N-glycans) to release intact glycans. In addition, we provide clients with fast and sensitive N-glycan quantification and characterization services.
Fig.2 The process of enzymatic release of N-glycan. (CD BioGlyco)
We also use Endo H and Endo F1, Endo F2, and Endo F3 to release N-glycans. Endo H specifically cleaves high mannose and some mixed N-glycans between two N-acetylglucosamine (GlcNAc) residues in the core region. It is particularly useful for distinguishing different N-glycan classes and studying glycoprotein processing in the endoplasmic reticulum. Endo F1, Endo F2, and Endo F3 have different specificities for different types of N-glycans. We understand that every research project has its own unique needs, so our services are highly customizable and provide comprehensive solutions covering a variety of biological sources. Our goal is to provide you with high-quality released N-glycans that are ideal for detailed structural characterization, quantitative analysis, and functional studies on a variety of analytical platforms.
Workflow
Publication Data
Journal: Pharmaceutics
IF: 5.5
Published: 2021
Results: This article focuses on the quantitative N-glycan profiling of therapeutic monoclonal antibodies using a middle-up level hydrophilic interaction liquid chromatography-high resolution mass spectrometry (HILIC-HRMS) analysis. It details an advanced analytical approach for characterizing the N-glycosylation patterns of these critical biopharmaceutical products. The study emphasizes the importance of precise glycan quantification for quality control, biosimilar development, and understanding the impact of glycosylation on the efficacy and safety of therapeutic antibodies. This publication showcases a robust method for comprehensive glycoprofiling, which is essential for the biopharmaceutical industry.
Applications
- Biopharmaceutical development: Essential for characterizing therapeutic glycoproteins (e.g., monoclonal antibodies, fusion proteins, vaccines) to ensure product consistency, efficacy, and safety.
- Disease pathogenesis: Enables detailed studies of altered glycosylation patterns in disease states, providing insights into disease mechanisms and potential therapeutic targets.
- Fundamental glycoscience research: Supports basic research aimed at elucidating glycan structures, biosynthesis pathways, and their functions in cellular processes, development, and host-pathogen interactions.
- Food science and nutrition: Used in the analysis of glycoproteins in food products for quality assessment, allergenicity studies, and understanding nutrient bioavailability.
Advantages
- Exceptional specificity and efficiency: Our protocols utilize highly purified glycosidases, ensuring the precise cleavage of N-glycans from their protein backbone without non-specific degradation. This enzymatic precision guarantees the integrity of the released glycans, which is crucial for accurate downstream analysis.
- Maximized glycan recovery: Compared to harsher chemical methods, enzymatic release is gentle, significantly reducing the risk of glycan degradation, desialylation, or other structural modifications. This gentle approach maximizes the recovery of intact, native N-glycans, providing a more complete and accurate representation of the glycome.
- High reproducibility and consistency: With many years of experience, CD BioGlyco has developed and optimized robust, standardized protocols for N-glycan release. Our stringent quality control measures at every step ensure high reproducibility across batches and consistent results.
Frequently Asked Questions
The development of the enzymatic cleavage of N-glycan is a complex process. CD BioGlyco has advanced technology platforms and professional research teams in the field of enzymatic release. Our fast and effective strategy will greatly accelerate the project progress of our clients. Please feel free to contact us for more detailed information.
Associated Services
To help you achieve your complete glycomics research goals, CD BioGlyco offers a suite of complementary services that seamlessly integrate with our enzymatic release of N-glycan service. These offerings ensure a comprehensive solution from sample preparation to in-depth data analysis.
References
- Regan, P.; et al. Early stage glycosylation biomarkers in Alzheimer's disease. Medicines. 2019, 6(3): 92. (Open Access)
- Duivelshof, B.L.; et al. Quantitative N-glycan profiling of therapeutic monoclonal antibodies performed by middle-up level HILIC-HRMS analysis. Pharmaceutics. 2021, 13(11): 1744. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




